8-K: Brainstorm Cell Therapeutics Announces 1-for-15 Reverse Stock Split

Brainstorm Cell Therapeutics has approved a 1-for-15 reverse stock split of its common stock, effective September 30, 2024.

Summary

• Brainstorm Cell Therapeutics' Board of Directors has approved a one-for-fifteen reverse stock split of the company's common stock.
• This decision follows shareholder approval at the Annual Meeting on September 16, 2024, which authorized the board to implement a reverse stock split at a ratio between one-for-five and one-for-fifteen.
• The reverse stock split will be effective on September 30, 2024, at 11:59 p.m. ET.
• Trading on a split-adjusted basis will begin on October 1, 2024, under the existing ticker symbol BCLI and a new CUSIP number 10501E 300.
• Every fifteen shares of common stock will be converted into one share.
• No fractional shares will be issued; instead, shareholders will receive cash based on the closing price on the last trading day before the effective time, adjusted for the split.

Sentiment

Score: 3

Explanation: The announcement of a reverse stock split is generally viewed negatively by the market as it often indicates a struggling stock price and potential financial difficulties. While the company is taking steps to maintain its listing, the underlying issues that led to the need for a reverse split remain a concern.

Positives

• The reverse stock split was approved by shareholders, indicating support for the measure.
• The company will provide cash payments for fractional shares, ensuring shareholders are not disadvantaged.

Negatives

• A reverse stock split is often a sign of a struggling stock price and can be perceived negatively by investors.
• The company's ability to regain compliance with the minimum bid price requirement is uncertain.

Risks

• The company's ability to regain compliance with the minimum bid price requirement is a risk.
• The effectiveness of the reverse stock split in improving the stock price is not guaranteed.
• There is a risk that the stock may not continue to be listed on Nasdaq.
• The company's financial condition is a risk factor that could impact future performance.

Future Outlook

The company's future performance is subject to various risks and uncertainties, including its ability to regain compliance with the minimum bid price requirement, the effectiveness of the reverse stock split, the continued listing of the Common Stock on Nasdaq, and the company's financial condition.

Management Comments

• The Board of Directors approved the reverse stock split following shareholder authorization.

Industry Context

Reverse stock splits are often used by companies to increase their stock price and maintain listing requirements on exchanges like Nasdaq. This action is not uncommon in the biotech industry, especially for companies facing financial challenges or low stock prices.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from major exchanges due to low share prices.
• Many biotech companies with promising but yet-to-be-commercialized products have used reverse stock splits to maintain their listing status.
• For example, companies like Athersys and Ocugen have also implemented reverse stock splits in the past to meet Nasdaq's minimum bid price requirements.
• The success of a reverse stock split in the long term depends on the company's ability to improve its financial performance and market perception.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but the value of their holdings should remain the same immediately after the split.
• The reverse stock split may impact investor confidence and the company's ability to raise capital in the future.
• The company's employees may be affected by the uncertainty surrounding the company's financial health.

Next Steps

• The reverse stock split will be effective on September 30, 2024.
• Trading on a split-adjusted basis will begin on October 1, 2024.

Key Dates

Keywords

reverse stock split, common stock, BCLI, Nasdaq, shareholders, stock price, compliance